| 1 |
Fenton GA, Mitchell DA. Cellular Cancer Immunotherapy Development and Manufacturing in the Clinic. Clin Cancer Res 2023;29:843-57. [PMID: 36383184 DOI: 10.1158/1078-0432.CCR-22-2257] [Reference Citation Analysis]
|
| 2 |
Liu Y, Sperling AS, Smith EL, Mooney DJ. Optimizing the manufacturing and antitumour response of CAR T therapy. Nat Rev Bioeng 2023. [DOI: 10.1038/s44222-023-00031-x] [Reference Citation Analysis]
|
| 3 |
Huang KC, Lai CY, Hung WZ, Chang HY, Lin PC, Chiang SF, Ke TW, Liang JA, Shiau AC, Yang PC, Chen WT, Chao KSC. A Novel Engineered AAV-Based Neoantigen Vaccine in Combination with Radiotherapy Eradicates Tumors. Cancer Immunol Res 2023;11:123-36. [PMID: 36315960 DOI: 10.1158/2326-6066.CIR-22-0318] [Reference Citation Analysis]
|
| 4 |
Hiltensperger M, Krackhardt AM. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells. Front Immunol 2023;14:1121030. [PMID: 36949949 DOI: 10.3389/fimmu.2023.1121030] [Reference Citation Analysis]
|
| 5 |
Kizerwetter M, Pietz K, Tomasovic LM, Spangler JB. Empowering gene delivery with protein engineering platforms. Gene Ther 2022. [PMID: 36529795 DOI: 10.1038/s41434-022-00379-6] [Reference Citation Analysis]
|
| 6 |
Mai D, June CH, Sheppard NC. In vivo gene immunotherapy for cancer. Sci Transl Med 2022;14. [DOI: 10.1126/scitranslmed.abo3603] [Reference Citation Analysis]
|
| 7 |
Sun Y, Yuan Y, Zhang B, Zhang X. CARs: a new approach for the treatment of autoimmune diseases. Sci China Life Sci 2022. [PMID: 36346550 DOI: 10.1007/s11427-022-2212-5] [Reference Citation Analysis]
|
| 8 |
Nahmad AD, Lazzarotto CR, Zelikson N, Kustin T, Tenuta M, Huang D, Reuveni I, Nataf D, Raviv Y, Horovitz-Fried M, Dotan I, Carmi Y, Rosin-Arbesfeld R, Nemazee D, Voss JE, Stern A, Tsai SQ, Barzel A. In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice. Nat Biotechnol 2022;40:1241-9. [PMID: 35681059 DOI: 10.1038/s41587-022-01328-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 9 |
Zhang X, Jin X, Sun R, Zhang M, Lu W, Zhao M. Gene knockout in cellular immunotherapy: Application and limitations. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215736] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 10 |
Finck AV, Blanchard T, Roselle CP, Golinelli G, June CH. Engineered cellular immunotherapies in cancer and beyond. Nat Med 2022;28:678-89. [PMID: 35440724 DOI: 10.1038/s41591-022-01765-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 11 |
Tang TCY, Xu N, Nordon R, Haber M, Micklethwaite K, Dolnikov A. Donor T cells for CAR T cell therapy. Biomark Res 2022;10:14. [PMID: 35365224 DOI: 10.1186/s40364-022-00359-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Li Y, Bao Q, Yang S, Yang M, Mao C. Bionanoparticles in cancer imaging, diagnosis, and treatment. VIEW. [DOI: 10.1002/viw.20200027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
Xin T, Cheng L, Zhou C, Zhao Y, Hu Z, Wu X. In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy. Front Oncol 2022;12:809754. [PMID: 35223491 DOI: 10.3389/fonc.2022.809754] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 14 |
Bezeljak U. Cancer gene therapy goes viral: viral vector platforms come of age. Radiol Oncol 2022;56:1-13. [PMID: 35148469 DOI: 10.2478/raon-2022-0002] [Reference Citation Analysis]
|
| 15 |
Luginbuehl V, Abraham E, Kovar K, Flaaten R, Müller AM. Better by design: What to expect from novel CAR-engineered cell therapies? Biotechnol Adv 2022;:107917. [PMID: 35149146 DOI: 10.1016/j.biotechadv.2022.107917] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 16 |
Gao TA, Chen YY. T cells to fix a broken heart. Science 2022;375:23-4. [PMID: 34990255 DOI: 10.1126/science.abn0851] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 17 |
Geanta M, Boata A, Brand A, Cucos B, Lehrach H. Precision Medicine in Oncology and Cancer Therapeutics. Precision Medicine in Clinical Practice 2022. [DOI: 10.1007/978-981-19-5082-7_3] [Reference Citation Analysis]
|
| 18 |
De Bousser E, Callewaert N, Festjens N. T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy. Cancers (Basel) 2021;13:6067. [PMID: 34885176 DOI: 10.3390/cancers13236067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 19 |
Irving M, Lanitis E, Migliorini D, Ivics Z, Guedan S. Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells. Hum Gene Ther 2021;32:1044-58. [PMID: 34662233 DOI: 10.1089/hum.2021.173] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 20 |
Tickner ZJ, Farzan M. Riboswitches for Controlled Expression of Therapeutic Transgenes Delivered by Adeno-Associated Viral Vectors. Pharmaceuticals (Basel) 2021;14:554. [PMID: 34200913 DOI: 10.3390/ph14060554] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
